The PMPRB has outlived its usefulness

While patients would undoubtedly like lower drug prices, they don’t want PMPRB actions to lead to developers deciding not to launch new medicines in Canada.

Canadians with unmet health-care needs whose quality of life or longevity depends on access to new innovative medicines are the losers in this debacle, writes Nigel Rawson. Unsplash photograph by Towfiqu Barbhuiya

Opinion

BY NIGEL RAWSON

June 26, 2023

The Patented Medicine Prices Review Board (PMPRB), Canada’s drug-price regulator, is meant to prevent time-limited, patent monopolies granted for new medicines from being abused by excessive prices. But correspondence submitted to the House

To keep reading, subscribe and become a political insider.

Only $7.76 a week for an annual subscription.

Enjoy unlimited website access and the digital newspaper.

Cancel anytime.

Already a Subscriber?

Get Weekend Point of View Newsletter

A round up of the past weekâ€™s opinion writers and columnists on Saturdays and Sundays.

By entering your email address you consent to receive email from The Hill Times containing news, analysis, updates and offers. You may unsubscribe at any time. See our privacy policy